Co-inhibition of Serine-Threonine-Tyrosine Kinase 1 and Epidermal Growth Factor Receptor as improved targeted therapy in Non-Small Cell Lung Cancer.

Project Details


Lung cancer is the deadliest cancer in the world. An important subgroup of patients harbours mutations in the Epidermal Growth Factor Receptor (EGFR) making them sensitive to EGFR inhibitors. Despite a promising increase in free survival progression observed in clinical trials, the overall survival benefits remain limited and there are no definitive cures.
We have performed a high-throughput screen in order to identify additional targets involved in the subset of cancers in which EGFR acts as a driver mutation. We have identified serine/threonine/tyrosine kinase-1 (STYK1) as a potential relevant target for a combinational therapy with EGFR inhibitors. Remarkably, STYK1 is significantly overexpressed in lung cancer cells and it is directly associated with poor prognosis in NSCLC. Furthermore, STYK1 promotes tumour progression and stimulates cell invasion and metastasis. We postulate that inhibition of STYK1 could sensitize lung cancer cells to the therapeutic effect displayed by the already clinically available EGFR inhibitors, acting as an improved targeted combinational therapy.
Effective start/end date1/10/1730/09/21


  • lung cancer

Flemish discipline codes

  • Cancer biology